Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...